nach oben

Erschienen in:

31.10.2019

Correlation between disease severity factors and EQ-5D utilities in chronic obstructive pulmonary disease

verfasst von: Cristina Esquinas, Maria A. Ramon, Alexa Nuñez, Jesús Molina, José A. Quintano, Miguel Roman-Rodríguez, Karlos Naberan, Carl Llor, Carlos Roncero, Marc Miravitlles, Miriam Barrecheguren

Erschienen in: Quality of Life Research | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Impaired health-related quality of life (HRQoL) is associated with poor health outcomes in chronic obstructive pulmonary disease (COPD). The aim of this study was to determine health utilities in patients with COPD and to identify the variables with the greatest impact.

Methods

This is a pooled analysis of data from 4 observational studies performed in stable COPD patients. Evaluation of patient HRQoL utilities was performed using the Spanish version of the self-administered EuroQoL 5 Dimensions (EQ-5D) questionnaire. EQ-5D utilities were described and compared according to several markers of disease severity.

Results

6198 patients reported a mean (SD) EQ-5D index of 0.67 (0.26). A linear dose response relationship between EQ-5D utility and modified Medical Research Council (mMRC) score, forced expiratory volume in one 1 s (% predicted), COPD hospital admissions in the previous year, self-reported daily walking time, Charlson index, body mass index, obstruction, dyspnoea and exacerbation (BODEx) index, COPD assessment test (CAT), hospital anxiety and depression scale was observed (p for trend < 0.001). In multivariate analysis, patients reporting lower utility values were those with more dyspnoea, more comorbidities, using long-term oxygen therapy, with previous hospitalisations due to a COPD exacerbation and higher (worse) CAT score.

Conclusion

HRQoL measures such as EQ-5D can assist clinicians to understand the impact of respiratory disease on COPD patients.

Nur mit Berechtigung zugänglich

Miravitlles, M., Soler-Cataluña, J. J., Calle, M., Molina, J., Almagro, P., Quintano, J. A., et al. (2017). Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological treatment of stable chronic obstructive pulmonary disease. Archivos de Bronconeumologia,53, 324–335.PubMed

Ståhl, E., Lindberg, A., Jansson, S. A., Rönmark, E., Svensson, K., Andersson, F., et al. (2005). Health-related quality of life is related to COPD disease severity. Health and Quality of Life Outcomes,3, 56.CrossRef

Doll, H., & Miravitlles, M. (2005). Quality of life in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: A review of the literature. Pharmacoeconomics,23, 345–363.CrossRef

Jones, P., Miravitlles, M., van der Molen, T., & Kulich, K. (2012). Beyond FEV1 in COPD—a review of patient-reported outcomes and their measurement using a new generation of instruments. The International Journal of Chronic Obstructive Pulmonary Disease,7, 697–709.CrossRef

Moayeri, F., Hsueh, Y. S., Clarke, P., Hua, X., & Dunt, D. (2016). Health state utility value in chronic obstructive pulmonary disease (COPD); The challenge of heterogeneity: A systematic review and meta-analysis. COPD,13, 380–398.CrossRef

The EuroQol Group. (1990). EuroQol—a new facility for measurement of health related quality of life. Health Policy,16, 199–208.CrossRef

Briggs, A. H., Glick, H. A., Lozano-Ortega, G., Spencer, M., Calverley, P. M., Jones, P. W., et al. (2010). Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal,35, 532–539.CrossRef

Cross, J., Elender, F., Barton, G., Clark, A., Shepstone, L., Blyth, A., et al. (2010). A randomised controlled equivalence trial to determine the effectiveness and cost-utility of manual chest physiotherapy techniques in the management of exacerbations of chronic obstructive pulmonary disease (MATREX). Health Technology Assessment,14, 1–147.CrossRef

Pickard, A. S., Wilke, C., Jung, E., Patel, S., Stavem, K., & Lee, T. A. (2008). Use of a preference based measure of health (EQ-5D) in COPD and asthma. Respiratory Medicine,102, 519–536.CrossRef

10.

Rutten-van Mölken, M. P., Oostenbrink, J. B., Tashkin, D. P., Burdkhart, D., & Monz, B. U. (2006). Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest,130, 1117–1128.CrossRef

11.

Miravitlles, M., Naberan, K., Cantoni, J., & Azpeitia, A. (2011). Socioeconomic status and health-related quality of life of patients with chronic obstructive pulmonary disease. Respiration,82, 402–408.CrossRef

12.

Miravitlles, M., Barrecheguren, M., & Román-Rodríguez, M. (2015). Frequency and characteristics of different clinical phenotypes of chronic obstructive pulmonary disease. The International Journal of Tuberculosis and Lung Disease,19, 992–998.CrossRef

13.

Miravitlles, M., Llor, C., de Castellar, R., Izquierdo, I., Baró, E., & Donado, E. (2009). Validation of the COPD severity score for use in primary care: The NEREA study. European Respiratory Journal,33, 519–527.CrossRef

14.

Miravitlles, M., Molina, J., Quintano, J. A., Campuzano, A., Pérez, J., & Roncero, C. (2014). Factors associated with depression and severe depression in patients with COPD. Respiratory Medicine,108, 1615–1625.CrossRef

15.

Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994). Validation of a combined comorbidity index. Journal of Clinical Epidemiology,47, 1245–1251.CrossRef

16.

Bestall, J. C., Paul, E. A., Garrod, R., Garnham, R., Jones, P. W., & Wedzicha, J. A. (1999). Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax,54, 581–586.CrossRef

17.

Celli, B. R., & MacNee, W. (2004). Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. European Respiratory Journal,23, 932–946.CrossRef

18.

Soler-Cataluña, J. J., Martínez-García, M. A., Sánchez, L. S., Tordera, M. P., & Sánchez, P. R. (2009). Severe exacerbations and BODE index: Two independent risk factors for death in male COPD patients. Respiratory Medicine,103, 692–699.CrossRef

19.

Ramon, M. A., Esquinas, C., Barrecheguren, M., Pleguezuelos, E., Molina, J., Quintano, J. A., et al. (2017). Self-reported daily walking time in COPD: Relationship with relevant clinical and functional characteristics. The International Journal of Chronic Obstructive Pulmonary Disease,12, 1173–1181.CrossRef

20.

Zigmond, A., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica,67, 361–370.CrossRef

21.

Badia, X., Roset, M., Montserrat, S., Herdman, M., & Segura, A. (1999). The Spanish version of EuroQol: A description and its applications. European Quality of Life scale. Medicina Clínica (Barc),112(Suppl. 1), 79–85.

22.

Nolan, C. M., Longworth, L., Lord, Joanne, Canavan, J. L., Jones, S. E., Kon, S. S. C., et al. (2016). The EQ-5D-5L health status questionnaire in COPD: Validity, responsiveness and minimum important difference. Thorax,71, 493–500.CrossRef

23.

Miravitlles, M., Huerta, A., Valle, M., García-Sidro, P., Forné, C., Crespo, C., et al. (2015). Clinical variables impacting on the estimation of utilities in chronic obstructive pulmonary disease. The International Journal of Chronic Obstructive Pulmonary Disease,10, 367–377.CrossRef

24.

Miravitlles, M., Soriano, J. B., García-Río, F., Muñoz, L., Duran-Tauleria, E., Sanchez, G., et al. (2009). Prevalence of COPD in Spain: Impact of undiagnosed COPD on quality of life and daily activities. Thorax,64, 863–868.CrossRef

25.

Encuesta Nacional de Salud de España (2011–2012). Spanish National Health Survey 2011–2012. Latest published data, 2013. Accessed October 22, 2017, from http://www.ine.es/jaxi/menu.do;jsessionid=F1AC5C5327BC8A876380E258216895FA.jaxi01?type=pcaxis&path=/t15/p419&file=inebase&L=1.

26.

Jones, P. W., & Agusti, A. G. (2006). Outcomes and markers in the assessment of chronic obstructive pulmonary disease. European Respiratory Journal,27, 822–832.CrossRef

27.

Tsiligianni, I., Kocks, J., Tzanakis, N., Siafakas, N., & van der Molen, T. (2011). Factors that influence disease-specific quality of life or health status in patients with COPD: A review and meta-analysis of Pearson correlations. Primary Care Respiratory Journal,20, 257–268.CrossRef

28.

Miravitlles, M., Calle, M., Alvarez-Gutierrez, F., Gobartt, E., López, F., & Martín, A. (2006). Exacerbations, hospital admissions and impaired health status in chronic obstructive pulmonary disease. Quality of Life Research,15, 471–480.CrossRef

29.

Domingo-Salvany, A., Lamarca, R., Ferrer, M., Garcia-Aymerich, J., Alonso, J., Félez, M., et al. (2006). Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine,166(5), 680–685.CrossRef

30.

Brien, S. B., Stuart, B., Dickens, A. P., Kendrick, T., Ejordan, R., Adab, P., et al. (2018). Independent determinants of disease-related quality of life in COPD—scope for non pharmacologic interventions? The International Journal of Chronic Obstructive Pulmonary Disease,13, 247–256.CrossRef

31.

Martinez, C., Costan, J., Alcázar, B., Garcia-Polo, C., Ruiz, L. A., Herrejón, A., et al. (2016). Factors associated with depression in COPD: A multicenter study. Lung,194, 335–343.CrossRef

32.

Miravitlles, M., Molina, J., Quintano, J. A., Campuzano, A., Pérez, J., & Roncero, C. (2018). Depressive status explains a significant amount of the variance in COPD assessment test (CAT) scores. The International Journal of Chronic Obstructive Pulmonary Disease,13, 823–831.CrossRef

33.

Sundh, J., Ställberg, B., Lisspers, K., Montgomery, S. M., & Janson, C. (2011). Co-morbidity, body mass index and quality of life in COPD using the Clinical COPD Questionnaire. COPD,8, 173–181.CrossRef

34.

Ng, T. P., Niti, M., Tan, W. C., Cao, Z., Ong, K. C., & Eng, P. (2007). Depressive symptoms and chronic obstructive pulmonary disease: Effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Archives of Internal Medicine,167, 60–67.CrossRef

35.

Lacasse, Y., Rousseau, L., & Maltais, F. (2001). Prevalence of depressive symptoms and depression in patients with severe oxygen-dependent chronic obstructive pulmonary disease. Journal of Cardiopulmonary Rehabilitation and Prevention,21, 80–86.CrossRef

36.

Miravitlles, M., & Ribera, A. (2017). Undrestanding the impact of symptoms on the burden of COPD. Respiratory Research,18, 67.CrossRef

37.

Miravitlles, M., Molina, J., Naberan, K., Cots, J. M., Ros, F., Llor, C., et al. (2007). Factors determining the quality of life of patients with COPD in primary care. Therapeutic Advances in Respiratory Disease,1, 85–92.CrossRef

38.

Jones, P., Brusselle, G., Dal-Negro, R. W., Ferrer, M., Kardos, P., Levy, M. L., et al. (2012). Patient-centred assessment of COPD in primary care: Experience from a cross-sectional study of health-related quality of life in Europe. Primary Care Respiratory Journal,21(3), 329–336.CrossRef

39.

Pleguezuelos, E., Esquinas, C., Moreno, E., Ll, Guirao, Ortiz, J., García-Alsina, J., et al. (2016). Muscular dysfunction in COPD: Systemic effect or deconditioning? Lung,194, 249–257.CrossRef

40.

Matkovic, Z., Cvetko, D., Rahelic, D., Esquinas, C., Zarak, M., Miravitlles, M., et al. (2017). Nutritional status of patients with chronic obstructive pulmonary disease in relation to their physical performance. COPD,14, 626–634.CrossRef

Titel: Correlation between disease severity factors and EQ-5D utilities in chronic obstructive pulmonary disease
verfasst von: Cristina Esquinas
Maria A. Ramon
Alexa Nuñez
Jesús Molina
José A. Quintano
Miguel Roman-Rodríguez
Karlos Naberan
Carl Llor
Carlos Roncero
Marc Miravitlles
Miriam Barrecheguren
Publikationsdatum: 31.10.2019
Verlag: Springer International Publishing
Erschienen in: Quality of Life Research / Ausgabe 3/2020
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-019-02340-4

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Correlation between disease severity factors and EQ-5D utilities in chronic obstructive pulmonary disease

Abstract

Purpose

Methods

Results

Conclusion

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Psychometric evaluation of the Participation and Activity Inventory for Children and Youth (PAI-CY) 0–2 years with visual impairment

The association between health-related quality of life and noise or light sensitivity in survivors of a mild traumatic brain injury

The construct validity and responsiveness of the EQ-5D-5L, AQL-5D and a bespoke TTO in acute asthmatics

Health-related quality of life and exercise-based cardiac rehabilitation in contemporary acute coronary syndrome patients: a systematic review and meta-analysis

Does recall period matter? Comparing PROMIS® physical function with no recall, 24-hr recall, and 7-day recall

Factors contributing to the ceiling effect of the EQ-5D-5L: an analysis of patients with prostate cancer judged “no-problems”